MAPT and Alzheimer disease: ARHL was not associated with the change rate of Aβ42 (Figure 2A), but with the faster elevation rates of CSF tau (Figure 2B) and ptau181 (Figure 2C) in HC or preclinical AD, after adjustment for age, gender, education, APOE4 status, DM2, hypertension, hyperlipidemia, BMI, and extracted CSF volume.